79739-22-3

Usage

Uses

Used in Scientific Research:
6-Chloro-[3,4']-bipyridine is used as a research compound for various scientific studies and experiments. Its unique structure and properties make it a valuable tool in the field of chemistry and related disciplines.
Due to the limited information regarding the applications of this chemical, it is important to note that further studies and research are needed to fully understand its potential uses and benefits. The toxic and irritating nature of 6-Chloro-[3,4']-bipyridine also necessitates the development of safe handling procedures and protocols to minimize risks associated with its use.

Upstream product

• 106154-29-4 6-benzyloxy-3,4'-bipyridine 
• 106154-27-2 6'-methoxy-4,3'-bipyridine 
• 62749-34-2 1,2-dihydro-2-oxo-5-(4-pyridinyl)-pyridine 

Downstream Products

• 79739-33-6 5-(4-pyridyl)pyridin-2-amine 

Relevant academic research and scientific papers

A CONVENIENT SYNTHESIS OF 3,4'-BIPYRIDINE

3,4'-Bipyridine was synthesized from 6-methoxy-3,4'-bipyridine or 6-benzyloxy-3,4'-bipyridine via 6-chloro-3,4'-bipyridine.The chloro derivative was catalytically dechlorinated into the corresponding 3,4'-bipyridine.

5(Pyridinyl)pyridin-2-amines

5-PY-6-Q-pyridin-2-amines (I) or pharmaceutically acceptable acid-addition salts thereof are useful cardiotonics, where Q is hydrogen or lower-alkyl, and PY is 4-pyridinyl or 4-pyridinyl having one or two lower-alkyl substituents. Their preparation from the corresponding 5-PY-6-Q-2(1H-pyridinones via the corresponding 2-halo-5-PY-6-Q-pyridines is shown.

5-(Pyridinyl)pyridine-2-hydrazines, their preparation and their cardiotonic use

2-[R1 NHN(R)]-3-Q'-5-Py-6-Q-pyridines or pharmaceutically-acceptable acid-addition salts thereof are useful as cardiotonic agents, where Q is hydrogen or lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, Q' is hydrogen or halo, R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and R1 is hydrogen or when R is other than hydrogen R1 is the same as R. These compounds are prepared by reacting a 2-halo-3-Q'-5-PY-6-Q-pyridine with R1 NHNHR where 2-halo is bromo or chloro. Also shown are: the use of said 2-[R1 NN(R)]-3-Q'-5-PY-6-Q-pyridines as cardiotonic agents; and, the intermediates, 2,3-dihalo-5-PY-6-Q-pyridines, and their preparation from 3-nitro-5-PY-6-Q-2(1H)-pyridinones.

Compositions and their preparation

2-R2 -3-R3 -6-PY-5-Q-3H-imidazo[4,5-b]pyridines (I) or 1-R1 -2-R2 -6-PY-5-Q-1H-imidazo[4,5-b]pyridines (IA) or pharmaceutically-acceptable acid-addition salts thereof, where Q and R2 are each hydrogen or lower-alkyl, R1 and R3 are each hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkages and NB is di-(lower-alkyl)amino or 4-morpholinyl, at least one of R1 or R3 being hydrogen, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, which are useful as cardiotonics, are prepared by reacting 2-R3 NH-3-R1 NH-5-PY-6-Q-pyridine (II) with a tri-(lower-alkyl) ortho-(lower-alkanoate). Also shown are: the use of I or IA or salts in cardiotonic compositions and a method for increasing cardiac contractility; and, the preparation of the intermediates II, as well as intermediates used to prepare II.

1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use

1,3-Dihydro-1-R1 -3-R3 -6-PY-5-Q-2H-imidazo[4,5-b]pyridin-2-ones or -2-thiones or pharmaceutically-acceptable acid-addition salts thereof, which are useful as cardiotonic agents, where Q is hydrogen or lower-alkyl, R1 and R3 are each hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene and NB is di-(lower-alkyl)amino or 4-morpholinyl, at least one of R1 and R3 being hydrogen, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two substituents, are prepared by reacting a 2-R3 NH-3-R1 NH-5-PY-6-Q-pyridine with urea or carbonyldiimidazole to produce said -2-one or with an alkali metal xanthate, thiourea or thiocarbonyldiimidazole to produce said -2-thione. Also shown and claimed are cardiotonic compositions and a method for increasing cardiac contractility using said cardiotonic agents. Also shown are processes for preparing said intermediate 2-R3 NH-3-R1 NH-5-PY-6-Q-pyridines and other intermediates used in said processes.

5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use

2-R3 RN-3-R1 R'N-5-PY-6-Q-pyridines (I) or pharmaceutically-acceptable acid-addition salts thereof are useful as intermediates in the preparation of 1- or 3-substituted-1,3-dihydro-5-Q-6-PY-2H-imidazo[4,5-b]pyridin-2-ones or -2-thiones and also as intermediates for preparing 1- or 3-substituted-5-Q-6-PY-3H(or 1H)-imidazo[4,5-b]pyridines, where R1, R3, R, R', PY and Q are defined hereinbelow. Also shown are processes for preparing I and the following intermediates used therein: 2-halo-3-nitro-5-PY-6-Q-pyridines (III), 2-R3 RN-3-nitro-5-PY-6-Q-pyridines (V), 2-halo-5-PY-6-Q-pyridines (VII), 2-R3 RN-5-PY-6-Q-pyridines (VIII) and 2-R3 RN-3-halo-5-PY-6-Q-pyridines (IX) or salts thereof. Certain embodiments of II and VIII also are useful as cardiotonics and are shown as active components of cardiac compositions and methods for increasing cardiac contractility.